Garousi, J.; Xu, T.; Liu, Y.; Vorontsova, O.; Hober, S.; Orlova, A.; Tolmachev, V.; Gräslund, T.; Vorobyeva, A.
Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics 2022, 14, 1612.
https://doi.org/10.3390/pharmaceutics14081612
AMA Style
Garousi J, Xu T, Liu Y, Vorontsova O, Hober S, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A.
Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics. 2022; 14(8):1612.
https://doi.org/10.3390/pharmaceutics14081612
Chicago/Turabian Style
Garousi, Javad, Tianqi Xu, Yongsheng Liu, Olga Vorontsova, Sophia Hober, Anna Orlova, Vladimir Tolmachev, Torbjörn Gräslund, and Anzhelika Vorobyeva.
2022. "Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart" Pharmaceutics 14, no. 8: 1612.
https://doi.org/10.3390/pharmaceutics14081612
APA Style
Garousi, J., Xu, T., Liu, Y., Vorontsova, O., Hober, S., Orlova, A., Tolmachev, V., Gräslund, T., & Vorobyeva, A.
(2022). Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics, 14(8), 1612.
https://doi.org/10.3390/pharmaceutics14081612
